drugset / Trial / NCT00003430
L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors
Phase 1
Completed
40 enrolled
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI) · collab
Treatment
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of L-778,123 in treating patients with recurrent or refractory solid tumors.
Timeline
- Start
- 1998-04
- Primary completion
- 2000-04
- Completion
- 2000-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | L-778,123 | Small molecule | — | — |